The Lancet Publishes Results From Pivotal Study Of Eisai's Halaven? Injection In Pati

[News]

Eisai announced that results from the global Phase III clinical study "EMBRACE" (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus Eribulin) will be published online in The Lancet. The EMBRACE study showed that Halaven (eribulin mesylate) Injection demonstrated a statistically significant increase in overall survival (hazard ratio 0.81, 95% CI 0.66-0.99; p=0...

More... (http://www.medicalnewstoday.com/articles/218110.php)